Successful bridging from a peptide to a non peptide antagonist at the human tachykinin NK-2 receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 20, 2002, Pages 2945-2948

  Altamura, Maria ^a   Canfarini, Franca ^a   Catalioto, Rose Marie ^a   Guidi, Antonio ^a   Pasqui, Franco ^a   Renzetti, Anna R ^a   Triolo, Antonio ^a   Maggi, Carlo A ^a  

^a Menarini Ricerche SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROKININ 2 RECEPTOR; PEPTIDE; TACHYKININ;

ARTICLE; BEHAVIOR; BINDING AFFINITY; CHEMICAL ANALYSIS; CHEMICAL BINDING; CHEMICAL STRUCTURE; STEREOISOMERISM;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LIGANDS; MASS SPECTROMETRY; PEPTIDES; PEPTIDES, CYCLIC; RECEPTORS, NEUROKININ-2; SPECTROPHOTOMETRY, ULTRAVIOLET; STEREOISOMERISM;

EID: 0037152417     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00539-5     Document Type: Article

References (30)

1. Maggi C.A. Gen. Pharmac. 26:1995;911.
2. . For the therapeutic relevance of tachykinin NK-2 receptor selective antagonists in humans, see: (a) Van Schoor J., Joos G.F., Chasson B.L., Brouard R.J., Pauwels R.A. Eur. Respir. J. 12:1998;17 (b) Lördal M., Navalesi G., Theodorsson E., Maggi C.A., Hellström P.M. Br. J. Pharmacol. 134:2001;215.
3. . For the therapeutic relevance of tachykinin NK-2 receptor selective antagonists in humans, see: (a) Van Schoor J., Joos G.F., Chasson B.L., Brouard R.J., Pauwels R.A. Eur. Respir. J. 12:1998;17 (b) Lördal M., Navalesi G., Theodorsson E., Maggi C.A., Hellström P.M. Br. J. Pharmacol. 134:2001;215.
4. (a) Pavone V., Lombardi A., Nastri F., Saviano M., Maglio O., D'Auria G., Quartara L., Maggi C.A., Pedone C. J. Chem. Soc., Perkin Trans. 2. 1995;987
5. (b) Maggi C.A., Astolfi M., Giuliani S., Goso C., Manzini S., Meini S., Patacchini R., Pavone V., Pedone C., Quartara L., Renzetti A.R., Giachetti A. J. Pharmacol. Exp. Ther. 271:1994;1489
6. (c) Catalioto R.-M., Criscuoli M., Cucchi P., Giachetti A., Giuliani S., Lecci A., Lippi A., Patacchini R., Quartara L., Renzetti A.R., Tramontana M., Arcamone F., Maggi C.A. Br. J. Pharmacol. 123:1998;81
7. (d) Giannotti D., Perrotta E., Di Bugno C., Nannicini R., Harmat N.J.S., Giolitti A., Patacchini R., Renzetti A.R., Rotondaro L., Giuliani S., Altamura M., Maggi C.A. J. Med. Chem. 43:2000;4041
8. (e) Quartara L., Rovero P., Maggi C.M. Med. Res. Rev. 15:1995;139
9. (f) Emonds-Alt X., Proietto V., Van Broeck D., Vilain P., Advenier C., Neliat G., Le Fur G., Brelière J.C. Bioorg. Med. Chem. Lett. 3:1993;925
10. (g) Emonds-Alt X., Advenier C., Cognon C., Croci T., Daoui S., Ducoux J.P., Landi M., Naline E., Neliat G., Poncelet M., Proietto V., Van Broeck D., Vilain P., Soubrié P., Le Fur G., Maffrand J.P., Brelière J.C. Neuropeptides. 31:1997;449
11. (h) Cooper A.W.J., Adams H.S., Bell R., Gore P.M., McElroy A.B., Pritchard J.M., Smith P.W., Ward P. Bioorg. Med. Chem. Lett. 4:1994;1951
12. (i) Smith P.W., Cooper A.W.J., Bell R., Beresford I.J.M., Gore P.M., McElroy A.B., Pritchard J.M., Saez V., Taylor N.R., Sheldrick R.L.G., Ward P. J. Med. Chem. 38:1995;3772.
13. (a) Altamura, M.; Criscuoli, M.; Guidi, A.; Perrotta, E.; Maggi, C. A. WO00/08046, 2000; Chem. Abstr. 2000, 136, 166521.
14. (b) Harmat, N. J. S.; Gianotti, D.; Nannicini, R.; Perrotta, E.; Criscuoli, M.; Patacchini, R.; Renzetti, A. R.; Giuliani, S.; Altamura, M.; Maggi, C. A. Bioorg. Med. Chem. Lett. 2002, 12, 693.
15. (c) Valenza, S.; Cordero, F. M.; Brandi, A.; Guidi, A.; Altamura, M.; Giolitti, A.; Giuntini, F.; Pasqui, F.; Renzetti, A. R.; Maggi, C. A. J. Org. Chem. 2000, 65, 4003.
16. Patchett A.A., Nargund R.P. Annu. Rep. Med. Chem. 35:2000;289.
17. 7,8.
18. 1H NMR, mass spectrometry and had a purity by analytical HPLC of ≥95%.
19. i values were calculated according to the procedure described by: Munson P.J. Anal. Biochem. 107:1980;220.
20. 2 values were calculated from the parallel rightward shift of the NKA concentration response curve in the presence of the antagonists, according to: Tallarida, R. J.; Cowan, A.; Adler, M. W. Life Sci. 1979, 25, 637.
21. 2 values were calculated from the parallel rightward shift of the NKA concentration response curve in the presence of the antagonists, according to: Tallarida, R. J.; Cowan, A.; Adler, M. W. Life Sci. 1979, 25, 637.
22. Chou W.-C., Tan C.-W., Chen S.-F., Ku H. J. Org. Chem. 63:1998;10015.
23. . The three products were identified by the comparison of HPLC analyses and PMR spectra at 200 MHz, accomplished before and after the extraction of the crude reaction mixture with aqueous hydrochloric acid. Both UV spectroscopy and MS spectrometry were used as chromatographic revelators. For examples of carboxylic acids methyl esters acting as alkylating agents of amines see: Zaugg H.E., Helgren P.F., Schaefer A.D. J. Org. Chem. 28:1963;2617.
24. Clayden J., Pink J.H., Yasin S.A. Tetrahedron Lett. 39:1998;105.
25. Schneider H.-J., Kasper C., Palyulin V., Samoshin V.V. Supramol. Chem. 8:1997;225.
26. 12,13 on the room temperature NMR timescale: 2×2 dissymmetric isomers and 2×1 asymmetric anti isomer. Observed isomers in the PMR spectra, without the addition of external chiral substances: 3: Noteworthy, in one of compound 3 isomers, the two pyrazinic protons resonate as an AB system (δ=8.76 and 8.79 ppm, J=2.6 Hz).
27. Luna C8(2) 5 μm, 25 cm length, 4.6 mm internal diameter column. Mobile phase: A water, B acetonitrile, both containing 0.1% trifluoroacetic acid. Gradient conditions: from 20 to 80% B in 20 min, at a flow rate of 1 mL/min.
28. So far, we have not attempted to exploit this finding to know, by means of focussed experiments, which racemic mixture is most potent at the hNK-2 receptor.
29. Janssen L.H.M. Bioorg. Med. Chem. 6:1998;785. In this paper, the author argues that theoretical reasons could exist to survey the most potent active conformers amongst the less stable conformers of the isolated ligand candidate.
30. Liu J., Underwood D.J., Cascieri M.A., Rohrer S.P., Cantin L.-D., Chicchi G., Smith A.B. III, Hirschmann R. J. Med. Chem. 43:2000;3827. For a more general discussion concerning the conservation of symmetry in natural phenomena, see: Hargittai, I.; Hargittai, M. In Symmetry through the Eyes of a Chemist, 2nd ed., Plenum: New York and London, 1995; p 70, and references cited.